Skip to content

5-MeO-DMT: all studies

Page 73 of 110: studies 721 to 730 of 1,097, newest first. Back to the 5-MeO-DMT overview

Research

A Review of Aeruginascin and Potential Entourage Effect in Hallucinogenic Mushrooms

European Psychiatry June 1, 2022 Pierre Chue, A. Andreiev, E. Bucuci et al. 6 citations

Introduction The 5-HT 2A agonist classic psychedelic, psilocybin (O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine) is a tryptophan, indole-based alkaloid present in up to 2% of certain hallucinogenic “magic” mushroom species; typically Psilocybe azurescens, semilanceata, and cyanescens,. In addition, mushrooms may contain psilocin (4-hydroxy-N,N-dimethyltryptamine). Both are indolylalkylamines...

The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides.

Psychopharmacology June 1, 2022 Pablo Mallaroni, Natasha L. Mason, F R J Vinckenbosch et al. 16 citations

Novel psychedelics (NPs) are an expanding set of compounds, presenting new challenges for drug policy and opportunities for clinical research. Unlike their classical derivatives, little is known regarding their use profiles or their subjective effects. The purpose of this study was to compile usage patterns and adverse event rates for individual NPs belonging to each of three main psychedelic...

DOI: 10.1007/s00213-022-06142-4 (opens in new tab) Full text (opens in new tab) 2–4-bromo-2,5-dimethoxyphenylethanamine 2c-b 4-Acetoxy-N,N-Dimethyltryptamine 4-Aco-DMT Hallucinogen Lysergamide +4

Therapeutic Properties of Ayahuasca Components in Ischemia/Reperfusion Injury of the Eye

Biomedicines April 26, 2022 Anna Szilágyi, Barbara Takács, Réka Szekeres et al. 10 citations

Ischemic eye diseases are major causes of vision impairment. Thus, potential retinoprotective effects of N’N-dimethyltryptamine (DMT) were investigated. To inhibit its rapid breakdown by monoamine-oxidase A (MAO-A) enzyme, DMT was co-administered with harmaline, a β-carboline in the Amazonian Ayahuasca brew. Using ligation, 60 min of ischemia was provoked in eyes of rats, followed by 7 days of...

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

Molecules April 13, 2022 Henry Lowe, Ngeh J. Toyang, Blair Steele et al. 53 citations

The word “psychedelic” (psyche (i.e., the mind or soul) and delos (i.e., to show)) has Greek origin and was first coined by psychiatrist Humphry Osmond in 1956, who had been conducting research on lysergic acid diethylamide (LSD) at the time. Psychedelic drugs such as N,N-DMT/DMT (N,N-dimethyltryptamine), 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), LSD (lysergic acid diethylamide), MDMA...

Demystifying Psychedelic Treatments in Psychiatry: Is Ego Dissolution the Solution?

Psychiatric News April 1, 2022 Michael Avissar, A. J. Ambrose

A growing body of research suggests that psychedelic compounds may be useful for treating patients with certain disorders. As highlighted by several sessions at the APA Annual meeting, there’s a growing renewed interest in psychedelics, which are compounds that induce changes in thought, perception, and mood, in the clinical and research communities. Classic psychedelics refer to a subset whose...

In silico study of dimethyltryptamine analogues against 5-HT1B receptor: Molecular docking, dynamic simulations and ADMET prediction

Journal of Herbmed Pharmacology April 1, 2022 Neyder Contreras, Antistio Alvíz-amador, Isabella Manzur-Villalobos 5 citations

Introduction: The 5-HT1B receptor has a potential role in various psychiatric disorders such as depression, anxiety, and post-traumatic stress disorder. The objective of this study was to perform docking and molecular dynamics simulation to evaluate at atomic level the behavior of N,N-dimethyltryptamine (DMT) on 5-HT1B receptor.Methods: In this study, initially, a search for DMT was performed...

New Insights into the Chemical Composition of Ayahuasca

ACS Omega April 1, 2022 Luisina Castelli Rodríguez, Andrés Mariño López, Guillermo Moyna et al. 28 citations

Ayahuasca is a psychedelic beverage originally from the Amazon rainforest used in different shamanic settings for medicinal, spiritual, and cultural purposes. It is prepared by boiling in water an admixture of the Amazonian vine Banisteriopsis caapi, which is a source of β-carboline alkaloids, with plants containing N,N-dimethyltryptamine, usually Psychotria viridis. While previous studies have...

Springtime for psychopharmacology

Journal of Psychopharmacology March 1, 2022 Catherine Bird, A. H. Young

As we head into the (Northern Hemisphere) spring, the Journal publishes another set of papers which illustrate the robust health of the science of psychopharmacology. Once again, papers mostly focus on psychedelic drugs and related topics reflecting the zeitgeist (Young, 2022). de Wit et al. (2022) explore translational challenges and opportunities between clinical research and laboratory...